The Center for Drug Evaluation (CDE) is currently soliciting feedback on the 77th batch of chemical generic reference preparations, with a deadline set for December 20, 2023. This batch includes 26 new specifications and 57 additional specifications. However, 18 specifications did not pass the review process, primarily due to issues such as the absence of reference preparation status, discrepancies with domestically approved drugs regarding dosage ranges, and failures during re-review.- Flcube.com
Recent news:
-
Sino Biopharmaceutical Submits NDA for Anlotinib and Penpulimab Combo in HCC to NMPA -
Sihuan Pharmaceutical's Huisheng Pharm Strikes Exclusive Deal for Semaglutide Biosimilar in China -
Innovent Biologics' IBI354 Earns Breakthrough Therapy Designation for Ovarian Cancer Treatment -
CDE Includes Double-Crane's Hydroxocobalamine and Sanofi Genzyme's Fitusiran in Rare Disease Care Plan -
Apeiron Therapeutics Initiates Phase Ia/B Study for GTA182 in Solid Tumors with MTAP Deficiency
